1. Home
  2. RYTM vs SYNA Comparison

RYTM vs SYNA Comparison

Compare RYTM & SYNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • SYNA
  • Stock Information
  • Founded
  • RYTM 2008
  • SYNA 1986
  • Country
  • RYTM United States
  • SYNA United States
  • Employees
  • RYTM N/A
  • SYNA 1716
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • SYNA Computer peripheral equipment
  • Sector
  • RYTM Health Care
  • SYNA Technology
  • Exchange
  • RYTM Nasdaq
  • SYNA Nasdaq
  • Market Cap
  • RYTM 4.3B
  • SYNA 2.5B
  • IPO Year
  • RYTM 2017
  • SYNA 2002
  • Fundamental
  • Price
  • RYTM $65.77
  • SYNA $68.99
  • Analyst Decision
  • RYTM Strong Buy
  • SYNA Buy
  • Analyst Count
  • RYTM 12
  • SYNA 8
  • Target Price
  • RYTM $77.50
  • SYNA $94.29
  • AVG Volume (30 Days)
  • RYTM 631.5K
  • SYNA 376.3K
  • Earning Date
  • RYTM 08-05-2025
  • SYNA 08-07-2025
  • Dividend Yield
  • RYTM N/A
  • SYNA N/A
  • EPS Growth
  • RYTM N/A
  • SYNA N/A
  • EPS
  • RYTM N/A
  • SYNA 4.13
  • Revenue
  • RYTM $136,863,000.00
  • SYNA $1,038,900,000.00
  • Revenue This Year
  • RYTM $37.56
  • SYNA $13.82
  • Revenue Next Year
  • RYTM $74.99
  • SYNA $8.97
  • P/E Ratio
  • RYTM N/A
  • SYNA $16.63
  • Revenue Growth
  • RYTM 48.88
  • SYNA 10.60
  • 52 Week Low
  • RYTM $40.46
  • SYNA $41.80
  • 52 Week High
  • RYTM $69.89
  • SYNA $98.00
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 57.57
  • SYNA 66.84
  • Support Level
  • RYTM $60.80
  • SYNA $64.27
  • Resistance Level
  • RYTM $67.75
  • SYNA $66.70
  • Average True Range (ATR)
  • RYTM 2.08
  • SYNA 1.95
  • MACD
  • RYTM 0.26
  • SYNA 0.34
  • Stochastic Oscillator
  • RYTM 71.91
  • SYNA 96.04

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About SYNA Synaptics Incorporated $0.001 Par Value

Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. Geographically, it derives a majority of revenue from China. The company operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products.

Share on Social Networks: